02179.HK
Jiangsu Recbio Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 5.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -25.2%
- EBITDA
- +23.2%
- EBIT
- +15.2%
- EPS
- +14.1%
- Free cash flow
- +42.5%
- Operating cash flow
- +41.9%
Forward estimates
Based on analyst estimates
- Revenue
- -73.1%
- EBITDA
- +63.1%
- EPS
- +68.4%
Three-year CAGR
- Revenue
- +32.5%
- EBITDA
- +7.2%
- EBIT
- -3.0%
- Net income
- -5.7%
- EPS
- +3.4%
- Free cash flow
- +5.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026